Gilead’s Trodelvy Wins CHMP Support in 1L TNBC
FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
